- COMPASS IPO'd in September last year, at $17 per share - by December, shares had hit $59. Current market cap is $1.4bn.
- The company has developed a proprietary formulation of Psilocybin - the hallucinogenic found in magic mushrooms.
- Its approach is unique, with patients undergoing the treatment in the company of at least 1 trained professional therapist.
- The links between psychedelics and effective treatment for depressive disorders have been established, but the international governments and health authorities are less enthused.
- Data from Compass' Phase 2b trial ought to be available before the end of the year, but determining the chances of success is perhaps too tricky to make the bull case for COMPASS.
For further details see:
Compass Faces Tricky Road To Approval For Its Psychedelic Depressive Therapy